US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
*
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
AU2008202860B9
(en)
*
|
1995-04-27 |
2012-03-29 |
Amgen Fremont Inc. |
Human Antibodies Derived From Immunized Xenomice
|
EP1978033A3
(de)
*
|
1995-04-27 |
2008-12-24 |
Amgen Fremont Inc. |
Aus immunisiertem Xenomid abgeleitete menschliche Antikörper
|
AU4376400A
(en)
*
|
1995-04-27 |
2000-11-30 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
CA2219486A1
(en)
*
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
ATE274594T1
(de)
*
|
1995-06-07 |
2004-09-15 |
Jacob N Wohlstadter |
Methode zur erhöhung der enzymdiversität
|
US5919681A
(en)
*
|
1995-06-07 |
1999-07-06 |
Wohlstadter Jacob N |
Method for promoting enzyme diversity
|
US5914256A
(en)
*
|
1995-06-07 |
1999-06-22 |
Wohlstadter Jacob N |
Method for promoting enzyme diversity
|
JPH11510047A
(ja)
*
|
1995-07-21 |
1999-09-07 |
ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ |
HIV gp120の加水分解を触媒する組成物および方法
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
EP0966971A1
(de)
|
1996-04-23 |
1999-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Präventivum oder wirkstoff gegen hirnschlag/cerebrales ödem, mit il-8 inhibitor als aktivem inhaltsstoff
|
JP2000510692A
(ja)
|
1996-05-04 |
2000-08-22 |
ゼネカ リミテッド |
Ceaに対するモノクローナル抗体、その抗体を含む結合体、およびadeptシステムにおけるそれらの治療的使用
|
CA2616914C
(en)
|
1996-12-03 |
2012-05-29 |
Abgenix, Inc. |
Egfr-binding antibody
|
AU2008200005B2
(en)
*
|
1996-12-03 |
2012-05-17 |
Amgen Fremont Inc. |
Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom
|
US6080910A
(en)
*
|
1997-02-20 |
2000-06-27 |
Case Western Reserve University |
Transgenic knockout animals lacking IgG3
|
ES2312184T3
(es)
|
1997-03-21 |
2009-02-16 |
Chugai Seiyaku Kabushiki Kaisha |
Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
GB9711167D0
(en)
*
|
1997-05-31 |
1997-07-23 |
Babraham The Inst |
Telomere-associated chromosome fragmentation
|
WO1999008707A1
(fr)
|
1997-08-15 |
1999-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Preventifs et/ou medicaments contre le lupus erythemateux systemique, contenant un anticorps anti-recepteur d'il-6 comme ingredient actif
|
GB9823930D0
(en)
*
|
1998-11-03 |
1998-12-30 |
Babraham Inst |
Murine expression of human ig\ locus
|
WO2000026352A1
(fr)
|
1998-11-04 |
2000-05-11 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouvelles serine proteases de la famille de la trypsine
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
CZ302706B6
(cs)
|
1998-12-23 |
2011-09-14 |
Pfizer Inc. |
Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
EP1961818A3
(de)
|
1999-04-09 |
2008-09-10 |
Chugai Seiyaku Kabushiki Kaisha |
Neue fötale Gene
|
EP1188830B1
(de)
|
1999-06-02 |
2010-01-20 |
Chugai Seiyaku Kabushiki Kaisha |
Neues hämopoietin rezeptorprotein nr10
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
ES2307526T3
(es)
|
1999-08-23 |
2008-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Potenciadores de la expresion del antigeno hm1.24.
|
MXPA02001911A
(es)
|
1999-08-24 |
2003-07-21 |
Medarex Inc |
Anticuerpos ctla-4 humanos y sus usos.
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
AU6871900A
(en)
|
1999-09-06 |
2001-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Tsg-like gene
|
AU7491800A
(en)
*
|
1999-09-15 |
2001-04-17 |
Therapeutic Human Polyclonals, Inc. |
Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds
|
EP1486510B1
(de)
|
1999-09-21 |
2009-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Verwendung vom transportergen oatp-c zur screening von testsubstanzen
|
US8062638B1
(en)
|
1999-10-01 |
2011-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
CN100497624C
(zh)
|
2000-01-24 |
2009-06-10 |
杉山治夫 |
Wt1相互作用蛋白质wtip
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
US7560534B2
(en)
|
2000-05-08 |
2009-07-14 |
Celldex Research Corporation |
Molecular conjugates comprising human monoclonal antibodies to dendritic cells
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
DZ3494A1
(fr)
|
2001-01-05 |
2002-07-11 |
Pfizer |
Anticorps anti-recepteur du facteur de croissance i analogue a l'insuline
|
JP3986439B2
(ja)
|
2001-02-07 |
2007-10-03 |
中外製薬株式会社 |
造血器腫瘍の治療剤
|
JP2005507635A
(ja)
|
2001-02-12 |
2005-03-24 |
メダレックス, インク. |
Fcα受容体(CD89)に対するヒトモノクローナル抗体
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
IL161968A0
(en)
|
2001-11-14 |
2005-11-20 |
Centocor Inc |
Anti-il-6 antibodies, compositions, methods and uses
|
US7435871B2
(en)
|
2001-11-30 |
2008-10-14 |
Amgen Fremont Inc. |
Transgenic animals bearing human Igλ light chain genes
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
CN1638800A
(zh)
|
2002-01-09 |
2005-07-13 |
米德列斯公司 |
抗cd30的人类单克隆抗体
|
EP3192528A1
(de)
|
2002-02-14 |
2017-07-19 |
Chugai Seiyaku Kabushiki Kaisha |
Formularierung anti-il-6r antikörper-enthaltender lösungen die einen zucker als stabilisator beinhalten
|
ATE431406T1
(de)
|
2002-02-25 |
2009-05-15 |
Genentech Inc |
Neuer typ-1-cytokinrezeptor glm-r
|
AU2003220930A1
(en)
|
2002-03-29 |
2003-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Emthod of screening transporter inhibitor
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化n端ペプチドに対する抗体
|
JP2005529873A
(ja)
|
2002-04-12 |
2005-10-06 |
メダレックス インコーポレイテッド |
Ctla−4抗体を使用した治療の方法
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
EP1513934B1
(de)
|
2002-06-06 |
2011-03-02 |
Oncotherapy Science, Inc. |
Gene und proteine mit bezug zu menschlichem kolonkrebs
|
ES2361541T3
(es)
|
2002-06-06 |
2011-06-17 |
Oncotherapy Science, Inc. |
Genes y polipéptidos relacionados con cánceres de colon humanos.
|
JP4489591B2
(ja)
|
2002-08-27 |
2010-06-23 |
中外製薬株式会社 |
タンパク質溶液製剤の安定化方法
|
AU2003262087B2
(en)
|
2002-09-11 |
2010-11-11 |
Chugai Seiyaku Kabushiki Kaisha |
Protein purification method
|
TW200413539A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Genes and polypeptides relating to prostate cancers
|
TW200413725A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancers
|
WO2004035607A2
(en)
|
2002-10-17 |
2004-04-29 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
AU2003301576A1
(en)
|
2002-10-22 |
2004-05-13 |
Eisai Co., Ltd. |
Gene expressed specifically in dopamine-producing neuron precursor cells after termination of division
|
AU2003280643A1
(en)
|
2002-10-30 |
2004-05-25 |
Chugai Seiyaku Kabushiki Kaisha |
Membrane protein originating in mast cells
|
KR101329843B1
(ko)
|
2002-11-15 |
2013-11-14 |
젠맵 에이/에스 |
Cd25에 대한 인간 모노클로날 항체
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
ATE527278T1
(de)
|
2002-12-16 |
2011-10-15 |
Genmab As |
Humane monoklonale antikörper gegen interleukin 8 (il-8)
|
EP1613750B1
(de)
|
2003-03-19 |
2015-10-14 |
Amgen Fremont Inc. |
Antikörper gegen das t-zellen-immunglobulindomäne- und mucindomäne-1 (tim-1) antigen und verwendungen davon
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
US7491802B2
(en)
|
2003-05-28 |
2009-02-17 |
Takeda Pharmaceutical Company Limited |
Anti-BAMBI antibody and diagnostic or remedy for colon cancer and liver cancer
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
WO2005017155A1
(ja)
|
2003-06-18 |
2005-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
フコーストランスポーター
|
AU2004259398A1
(en)
|
2003-06-27 |
2005-02-03 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
US7396914B2
(en)
|
2003-08-04 |
2008-07-08 |
University Of Massachusetts |
SARS nucleic acids, proteins, antibodies, and uses thereof
|
EP1652923B1
(de)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Bei krebs überexprimiertes gen
|
JP2007521232A
(ja)
|
2003-08-08 |
2007-08-02 |
アブジェニックス・インコーポレーテッド |
副甲状腺ホルモン(pth)に対する抗体およびその使用
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
JPWO2005035754A1
(ja)
|
2003-10-14 |
2006-12-21 |
中外製薬株式会社 |
機能蛋白質を代替する二種特異性抗体
|
US7642341B2
(en)
|
2003-12-18 |
2010-01-05 |
Merck Serono S.A. |
Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
|
EP1533617A1
(de)
|
2003-11-19 |
2005-05-25 |
RMF Dictagene S.A. |
Angiogenese inhibierende Moleküle, deren Auswahl, Herstellung und Benutzung zur Behandlung und Diagnose von Krebs
|
CA2548185A1
(en)
|
2003-12-03 |
2005-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
Expression systems using mammalian .beta.-actin promoter
|
KR101374514B1
(ko)
|
2003-12-10 |
2014-03-13 |
메다렉스, 인코포레이티드 |
Ip―10 항체 및 그의 용도
|
DK2418220T3
(da)
|
2003-12-10 |
2017-11-06 |
Squibb & Sons Llc |
Interferon-alpha-antistoffer og anvendelser deraf
|
EP1710255A4
(de)
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
Modifizierte antikörper, die rezeptortrimere oder höhere multimere erkennen
|
CA2553946C
(en)
|
2004-02-06 |
2019-02-26 |
University Of Massachusetts |
Antibodies against clostridium difficile toxins and uses thereof
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
MXPA06010673A
(es)
|
2004-03-19 |
2007-06-20 |
Amgen Inc |
Reduccion del riesgo de anticuerpos humanos anti-humano a traves de manipulacion del gen v.
|
JP4938451B2
(ja)
|
2004-03-23 |
2012-05-23 |
オンコセラピー・サイエンス株式会社 |
非小細胞肺癌の診断のための方法
|
PL1737891T3
(pl)
|
2004-04-13 |
2013-08-30 |
Hoffmann La Roche |
Przeciwciała przeciw selektynie p
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
EA012622B1
(ru)
|
2004-06-01 |
2009-10-30 |
Домэнтис Лимитед |
Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
|
LT2662390T
(lt)
|
2004-06-21 |
2017-10-10 |
E. R. Squibb & Sons, L.L.C. |
Interferono-alfa receptoriaus-1 antikūnai ir jų panaudojimas
|
JP5112863B2
(ja)
|
2004-07-01 |
2013-01-09 |
ノヴォ ノルディスク アー/エス |
ヒト抗−kir抗体
|
MY145073A
(en)
|
2004-07-09 |
2011-12-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
US20080199437A1
(en)
|
2004-07-22 |
2008-08-21 |
Eisai Co., Ltd. |
Lrp4/Corin Dopaminergic Neuron Progenitor Cell Markers
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
MX2007003533A
(es)
|
2004-10-01 |
2007-05-23 |
Medarex Inc |
Metodos de tratar linfomas cd30 positivas.
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
CA3079874C
(en)
|
2004-10-22 |
2023-01-03 |
Revivicor, Inc. |
Ungulates with genetically modified immune systems
|
CA2587903A1
(en)
|
2004-11-17 |
2006-05-26 |
Amgen Fremont Inc. |
Fully human monoclonal antibodies to il-13
|
NZ555464A
(en)
|
2004-12-02 |
2010-03-26 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
EP1838737B1
(de)
|
2004-12-20 |
2011-04-06 |
Amgen Fremont Inc. |
Für humane matriptase spezifische bindungsproteine
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
ES2395953T3
(es)
|
2005-01-26 |
2013-02-18 |
Amgen Fremont Inc. |
Anticuerpos frente a interleucina-1 beta
|
EP1856278A2
(de)
|
2005-02-10 |
2007-11-21 |
Oncotherapy Science, Inc. |
Verfahren zur diagnose von blasenkrebs
|
JP2008530244A
(ja)
|
2005-02-18 |
2008-08-07 |
メダレックス, インク. |
フコシル残基を欠くcd30に対するモノクローナル抗体
|
TWI406870B
(zh)
|
2005-02-21 |
2013-09-01 |
Chugai Pharmaceutical Co Ltd |
A method of making a protein using hamster IGF-1
|
WO2006098464A1
(ja)
|
2005-03-14 |
2006-09-21 |
Link Genomics, Inc. |
前立腺がんの診断方法
|
ES2716874T3
(es)
|
2005-03-23 |
2019-06-17 |
Genmab As |
Anticuerpos contra cd38 para el tratamiento del mieloma múltiple
|
SI1876236T1
(sl)
|
2005-04-08 |
2014-11-28 |
Chugai Seiyaku Kabushiki Kaisha |
Protitelo, ki funkcionalno nadomesti faktor viii za koagulacijo krvi
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
EP3530736A3
(de)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
EP3501537A1
(de)
|
2005-06-30 |
2019-06-26 |
Janssen Biotech, Inc. |
Anti-il23-antikörper, zusammensetzungen, verfahren und verwendungen
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
EP1907859B1
(de)
|
2005-07-27 |
2011-03-02 |
Oncotherapy Science, Inc. |
Gene und polypeptide mit bezug zu prostatakrebs
|
JP5230420B2
(ja)
|
2005-08-18 |
2013-07-10 |
ゲンマブ エー/エス |
Cd4結合ペプチドおよび放射線による治療
|
EA016186B1
(ru)
|
2005-09-26 |
2012-03-30 |
Медарекс, Инк. |
Человеческие моноклональные антитела к cd70 и их применение
|
DK1939288T3
(da)
|
2005-09-29 |
2013-03-11 |
Eisai R&D Man Co Ltd |
T-celleadhæsionsmolekyle og antistof, der er rettet mod molekylet
|
WO2007043641A1
(ja)
|
2005-10-14 |
2007-04-19 |
Fukuoka University |
膵島移植における移植膵島障害抑制剤
|
BRPI0617664B8
(pt)
|
2005-10-21 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
|
JP5006330B2
(ja)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Il13に対するヒト抗体および治療的使用
|
CN101351221A
(zh)
|
2005-10-28 |
2009-01-21 |
明治制果株式会社 |
绿脓杆菌的外膜蛋白pa5158
|
CA2629453C
(en)
|
2005-11-10 |
2018-03-06 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
US8128934B2
(en)
|
2005-11-14 |
2012-03-06 |
Ribomic, Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
JP2009518446A
(ja)
|
2005-12-07 |
2009-05-07 |
メダレックス インコーポレーティッド |
Ctla−4抗体投与量漸増レジメン
|
JP5512128B2
(ja)
|
2005-12-08 |
2014-06-04 |
メダレックス・リミテッド・ライアビリティ・カンパニー |
フコシルgm1に対するヒトモノクローナル抗体および抗フコシルgm1を使用するための方法
|
PT1979001E
(pt)
|
2005-12-13 |
2012-07-13 |
Medimmune Ltd |
Proteínas de ligação específicas para factores de crescimento insulínicos e suas aplicações
|
WO2007077934A1
(ja)
|
2005-12-28 |
2007-07-12 |
Asubio Pharma Co., Ltd. |
抗ペリオスチン抗体およびそれを含有するペリオスチンが関与する疾患の予防または治療用医薬組成物
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
ES2586825T3
(es)
|
2006-01-12 |
2016-10-19 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos para OX-2/CD200 y usos de los mismos
|
EP1976883B1
(de)
|
2006-01-17 |
2012-10-03 |
Medarex, Inc. |
Monoklonale antikörper gegen cd30 ohne fucosyl- und xylosylreste
|
EP3135298B1
(de)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutische mittel für erkrankungen im zusammenhang mit choroidaler neovaskularisation
|
SG170804A1
(en)
|
2006-03-30 |
2011-05-30 |
Meiji Seika Kaisha |
Pseudomonas aeruginosa outer membrane protein pa0427
|
WO2007117410A2
(en)
|
2006-03-31 |
2007-10-18 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
WO2007118214A2
(en)
|
2006-04-07 |
2007-10-18 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Antibody compositions and methods for treatment of neoplastic disease
|
CN101495146B
(zh)
|
2006-04-07 |
2012-10-17 |
国立大学法人大阪大学 |
肌肉再生促进剂
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
WO2007129457A1
(ja)
|
2006-04-25 |
2007-11-15 |
The University Of Tokyo |
アルツハイマー病および癌の治療薬
|
DK2047863T3
(da)
|
2006-06-08 |
2013-09-16 |
Chugai Pharmaceutical Co Ltd |
Middel til forebyggelse eller behandling af inflammatoriske sygdomme
|
AU2007259739B2
(en)
|
2006-06-14 |
2013-03-07 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for promoting the growth of hematopoietic stem cells
|
CA2657385A1
(en)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Cell death inducer
|
JP5175729B2
(ja)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
腎疾患治療剤
|
TW200815474A
(en)
|
2006-08-03 |
2008-04-01 |
Astrazeneca Ab |
Antibodies alphaVbeta6 and uses thereof
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
WO2008020586A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
|
BRPI0714893A2
(pt)
|
2006-09-05 |
2013-05-28 |
Medarex Inc |
anticorpo monoclonal isolado ou uma porÇço de ligaÇço ao seu antÍgeno, um fragmento de anticorpo, um anticorpo mimÉtico, imunoconjugado, composiÇço molÉcula de Ácido nuclÉico isolada, vetor de expressço, cÉlula hospedeira, mÉtodo para preparar um anticorpo anti-bmp2 ou anti-bmp4, mÉtodo para tratar ou prevenir uma doenÇa associada com formaÇço àssea normal e ossificaÇço, hibridoma e metodo para preparar o anticorpo
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Adcc活性を増強させた抗体及びその製造方法
|
DK2081595T3
(da)
|
2006-09-26 |
2019-07-15 |
Genmab As |
Anti-cd38 plus corticosteroid plus et ikke-corticosteroid kemoterapeutikum til behandling af tumorer
|
AU2007301599B2
(en)
|
2006-09-28 |
2013-01-10 |
Merck Serono S.A. |
Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use
|
ES2625798T3
(es)
|
2006-10-02 |
2017-07-20 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
|
CA2665528C
(en)
|
2006-10-12 |
2018-01-23 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-ereg antibody
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
JP5378795B2
(ja)
|
2006-10-20 |
2013-12-25 |
中外製薬株式会社 |
抗hb−egf抗体を有効成分として含む医薬組成物
|
AU2007311946A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
EP2095826B1
(de)
|
2006-11-17 |
2012-12-26 |
The Research Foundation for Microbial Diseases of Osaka University |
Nervenelongationspromoter und elongationshemmer
|
CN101626782B
(zh)
|
2006-12-01 |
2013-03-27 |
梅达雷克斯公司 |
结合cd22的人抗体及其用途
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
EP2103628A4
(de)
|
2006-12-14 |
2012-02-22 |
Forerunner Pharma Res Co Ltd |
Monoklonaler anti-claudin-3-antikörper und die behandlung und diagnose von krebs unter dessen verwendung
|
AU2007333098A1
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind CD70 and uses thereof
|
EP2123676A4
(de)
|
2007-01-05 |
2011-01-05 |
Univ Tokyo |
Diagnose und behandlung von krebs unter verwendung von anti-prg-3-antikörpern
|
SG177982A1
(en)
|
2007-01-16 |
2012-02-28 |
Abbott Lab |
Methods for treating psoriasis
|
TWI438208B
(zh)
|
2007-01-23 |
2014-05-21 |
Chugai Pharmaceutical Co Ltd |
抑制慢性排斥反應之藥劑
|
EP3246407B1
(de)
|
2007-02-09 |
2019-04-03 |
Eisai R&D Management Co., Ltd. |
Gaba-neuronen-vorläuferzellen-marker 65b13
|
JP5241518B2
(ja)
|
2007-02-15 |
2013-07-17 |
国立大学法人九州大学 |
抗hmgb−1抗体を含む間質性肺疾患治療剤
|
EP3248617A3
(de)
|
2007-02-16 |
2018-02-21 |
Merrimack Pharmaceuticals, Inc. |
Antikörper gegen erbb3 und verwendungen davon
|
MX2009008706A
(es)
|
2007-02-21 |
2009-09-14 |
Univ Massachusetts |
Anticuerpos humanos contra el virus de la hepatitis c (hcv) y usos de los mismos.
|
JP5374360B2
(ja)
|
2007-02-27 |
2013-12-25 |
中外製薬株式会社 |
抗grp78抗体を有効成分として含む医薬組成物
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
AU2008234248C1
(en)
|
2007-03-29 |
2015-01-22 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
FI20075278A0
(fi)
|
2007-04-20 |
2007-04-20 |
Biotie Therapies Corp |
Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
US20100267934A1
(en)
|
2007-05-31 |
2010-10-21 |
Genmab A/S |
Stable igg4 antibodies
|
WO2008145140A2
(en)
|
2007-05-31 |
2008-12-04 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
WO2008153926A2
(en)
|
2007-06-05 |
2008-12-18 |
Yale University |
Inhibitors of receptor tyrosine kinases and methods of use thereof
|
US8722858B2
(en)
|
2007-06-25 |
2014-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Prominin-1 antibody having ADCC activity or CDC activity
|
WO2009001940A1
(ja)
|
2007-06-27 |
2008-12-31 |
Asubio Pharma Co., Ltd. |
ペリオスチンのExon-17部位によりコードされるペプチドに対する抗体を含む癌治療剤
|
WO2009008414A1
(ja)
|
2007-07-10 |
2009-01-15 |
Shionogi & Co., Ltd. |
Mmp13に対する中和活性を有するモノクローナル抗体
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
EP2185692A4
(de)
|
2007-08-10 |
2012-05-02 |
Medarex Inc |
Hco32 und hco27 sowie entsprechende beispiele
|
WO2009025196A1
(ja)
|
2007-08-20 |
2009-02-26 |
Oncotherapy Science, Inc. |
Foxm1ペプチドおよびこれを含む薬剤
|
PL2186889T3
(pl)
|
2007-08-20 |
2015-09-30 |
Oncotherapy Science Inc |
Peptyd CDCA1 i środek farmaceutyczny go zawierający
|
JP5294271B2
(ja)
|
2007-08-20 |
2013-09-18 |
オンコセラピー・サイエンス株式会社 |
Cdh3ペプチド及びこれを含む薬剤
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
EP2615114B1
(de)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
PL2769729T3
(pl)
|
2007-09-04 |
2019-09-30 |
Compugen Ltd. |
Polipeptydy i polinukleotydy i ich zastosowanie jako cel dla leków do wytwarzania leków i środków biologicznych
|
EP2497783A3
(de)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Antigenbindende Proteine mit Affinität für den Heparin-Binding Epidermal Growth Factor-Like-Wachstumsfaktor
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
AR068767A1
(es)
|
2007-10-12 |
2009-12-02 |
Novartis Ag |
Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
|
MX2010004007A
(es)
|
2007-10-15 |
2010-06-15 |
Chugai Pharmaceutical Co Ltd |
Metodo para la produccion de un anticuerpo.
|
KR20100115340A
(ko)
|
2007-10-19 |
2010-10-27 |
이무나스 파마 가부시키가이샤 |
Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용
|
EA201000718A1
(ru)
|
2007-11-02 |
2011-06-30 |
Новартис Аг |
Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
|
ES2445755T3
(es)
|
2007-11-07 |
2014-03-05 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
|
ES2556214T3
(es)
|
2007-11-12 |
2016-01-14 |
U3 Pharma Gmbh |
Anticuerpos para AXL
|
AU2008321840B2
(en)
|
2007-11-14 |
2014-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
AR069333A1
(es)
|
2007-11-15 |
2010-01-13 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos monoclonales que se unen al receptor tirosin quinasa anexelekto (axl), hibridomas que los producen y sus usos
|
EP2241332A4
(de)
|
2007-12-05 |
2011-01-26 |
Chugai Pharmaceutical Co Ltd |
Therapeutisches mittel gegen pruritus
|
EP2236604B1
(de)
|
2007-12-05 |
2016-07-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-nr10-antikörper und verwendung davon
|
US20110262425A1
(en)
|
2007-12-12 |
2011-10-27 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
ES2483942T5
(es)
|
2007-12-14 |
2017-02-06 |
Novo Nordisk A/S |
Anticuerpos contra NKG2D humano y usos de los mismos
|
AU2008342152B2
(en)
|
2007-12-25 |
2013-06-27 |
Meiji Seika Pharma Co., Ltd. |
Component protein PA1698 for type-III secretion system of Pseudomonas aeruginosa
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
EP2248826B1
(de)
|
2008-01-10 |
2013-06-12 |
Shionogi&Co., Ltd. |
Gegen pcrv gerichteter antikörper
|
US9274119B2
(en)
|
2008-01-11 |
2016-03-01 |
The University Of Tokyo |
Anti-CLDN6 antibody
|
CN102037007A
(zh)
|
2008-01-25 |
2011-04-27 |
奥尔胡斯大学 |
选择性外部位点抑制papp-a对igfbp-4的活性
|
EP2641612A1
(de)
|
2008-02-05 |
2013-09-25 |
Bristol-Myers Squibb Company |
Alpha-5-Beta-1-Antikörper und ihre Verwendungen
|
CN102936287B
(zh)
|
2008-02-08 |
2015-09-09 |
伊缪纳斯制药株式会社 |
能够特异性结合Aβ寡聚体的抗体及其应用
|
EP2274333A4
(de)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
Verfahren zur behandlung von psoriasis
|
EP2260863A1
(de)
|
2008-03-27 |
2010-12-15 |
Takara Bio, Inc. |
Prophylaxe-/therapiemittel für infektionserkrankungen
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
US8575314B2
(en)
|
2008-06-20 |
2013-11-05 |
National University Corporation Okayama University |
Antibody against oxidized LDL/β2GPI complex and use of the same
|
EP2815766B1
(de)
|
2008-08-05 |
2017-07-05 |
Novartis AG |
Zusammensetzungen und Verfahren für auf das Komplementprotein C5 gerichtete Antikörper
|
JP5692746B2
(ja)
|
2008-08-07 |
2015-04-01 |
国立大学法人 長崎大学 |
全身性疼痛症候群の治療または予防薬
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
MX2011001409A
(es)
|
2008-08-14 |
2011-03-29 |
Cephalon Australia Pty Ltd |
Anticuerpos anti-il-12/il-23.
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
DK2342226T3
(en)
|
2008-09-26 |
2016-09-26 |
Dana Farber Cancer Inst Inc |
HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
|
AU2009298458B2
(en)
|
2008-09-30 |
2015-10-08 |
Ablexis, Llc |
Non-human mammals for the production of chimeric antibodies
|
WO2010051288A1
(en)
|
2008-10-27 |
2010-05-06 |
Revivicor, Inc. |
Immunocompromised ungulates
|
PT2894165T
(pt)
|
2008-11-10 |
2023-03-17 |
Alexion Pharma Inc |
Métodos e composições para o tratamento de distúrbios associados ao complemento
|
AU2009324092A1
(en)
|
2008-12-03 |
2011-06-23 |
Genmab A/S |
Antibody variants having modifications in the constant region
|
EP2865689A1
(de)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F Polypeptide und Polynukleotide und Verwendungen davon als Arzneimittel-Target zur Herstellung von Arzneimitteln und Biologika
|
UA109633C2
(uk)
|
2008-12-09 |
2015-09-25 |
|
Антитіло людини проти тканинного фактора
|
AU2009329365B2
(en)
*
|
2008-12-18 |
2016-01-14 |
Roger Kingdon Craig |
Non-human transgenic animals expressing humanised antibodies and use thereof
|
JP5756292B2
(ja)
|
2008-12-22 |
2015-07-29 |
中外製薬株式会社 |
抗hs6st2抗体及びその用途
|
US8877449B2
(en)
|
2008-12-22 |
2014-11-04 |
Eisai R&D Management Co., Ltd. |
Method for obtaining pancreatic progenitor cell using NEPH3
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
EP2385114A4
(de)
|
2008-12-25 |
2012-08-08 |
Univ Tokyo |
Krebsbehandlungsdiagnose mit anti-tm4sf20-antikörper
|
WO2010074192A1
(ja)
|
2008-12-26 |
2010-07-01 |
国立大学法人東京大学 |
抗lgr7抗体を用いる癌の診断および治療
|
EA028336B1
(ru)
|
2009-03-05 |
2017-11-30 |
МЕДАРЕКС Л.Л.Си. |
Полностью человеческие антитела, специфические в отношении cadm1
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
JPWO2010110346A1
(ja)
|
2009-03-24 |
2012-10-04 |
独立行政法人理化学研究所 |
白血病幹細胞マーカー
|
WO2010112034A2
(en)
|
2009-04-02 |
2010-10-07 |
Aarhus Universitet |
Compositions and methods for treatment and diagnosis of synucleinopathies
|
CA2762187C
(en)
|
2009-04-08 |
2017-08-01 |
Olle Hernell |
New methods for treatment of inflammatory diseases
|
WO2010119691A1
(ja)
|
2009-04-16 |
2010-10-21 |
国立大学法人東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
JP5812418B2
(ja)
|
2009-04-17 |
2015-11-11 |
イムナス・ファーマ株式会社 |
Aβオリゴマーに特異的に結合する抗体およびその利用
|
US9062116B2
(en)
|
2009-04-23 |
2015-06-23 |
Infinity Pharmaceuticals, Inc. |
Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
|
EA201101572A1
(ru)
|
2009-04-27 |
2012-05-30 |
Новартис Аг |
Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
|
MA33279B1
(fr)
|
2009-04-27 |
2012-05-02 |
Novartis Ag |
Compositions et procédés pour l'augmentation de la croissance des muscles
|
EP2426149A4
(de)
|
2009-05-01 |
2013-01-23 |
Univ Tokyo |
Anti-cadherin-antikörper
|
PL2448970T3
(pl)
|
2009-05-04 |
2014-12-31 |
Abbvie Res B V |
Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo
|
CN104974250A
(zh)
|
2009-05-05 |
2015-10-14 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
WO2010151632A1
(en)
|
2009-06-25 |
2010-12-29 |
Bristol-Myers Squibb Company |
Protein purifacation by caprylic acid (octanoic acid ) precipitation
|
HUE055817T2
(hu)
|
2009-07-08 |
2021-12-28 |
Kymab Ltd |
Állatmodellek és terápiás molekulák
|
US20120204278A1
(en)
|
2009-07-08 |
2012-08-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
MY161541A
(en)
|
2009-07-31 |
2017-04-28 |
Shin Maeda |
Cancer metastasis inhibitor
|
EP2459594A1
(de)
|
2009-07-31 |
2012-06-06 |
N.V. Organon |
Vollständig menschliche antikörper gegen btla
|
ES2624835T3
(es)
|
2009-08-06 |
2017-07-17 |
Immunas Pharma, Inc. |
Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
|
DK2462162T3
(en)
|
2009-08-06 |
2017-01-16 |
Immunas Pharma Inc |
Antibodies that specifically bind to A-beta oligomers and their use
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
CN102574917A
(zh)
|
2009-08-17 |
2012-07-11 |
株式会社未来创药研究所 |
含有抗hb-egf抗体作为有效成分的药物组合物
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
RU2012114854A
(ru)
|
2009-09-14 |
2013-10-27 |
Эбботт Лэборетриз |
Способы лечения псориаза
|
US20120178910A1
(en)
|
2009-09-23 |
2012-07-12 |
Medarex, Inc. |
Cation exchange chromatography (methods)
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
RU2012124090A
(ru)
|
2009-11-09 |
2013-12-20 |
Алексион Фармасьютикалз, Инк. |
Реагенты и способы для определения клеток ii типа при pnh
|
CA2778953C
(en)
|
2009-11-13 |
2020-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
|
TWI630916B
(zh)
|
2009-11-13 |
2018-08-01 |
第一三共歐洲公司 |
供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
|
EP3431608A3
(de)
|
2009-11-17 |
2019-02-20 |
E. R. Squibb & Sons, L.L.C. |
Verfahren zur erhöhten proteinproduktion
|
EP3279215B1
(de)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Gezielte bindemittel gegen b7-h1
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
MX2012008108A
(es)
|
2010-01-11 |
2012-10-03 |
Alexion Pharma Inc |
Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
TR201806936T4
(tr)
|
2010-01-29 |
2018-06-21 |
Chugai Pharmaceutical Co Ltd |
Anti-dll3 antikoru.
|
SI3095871T1
(sl)
*
|
2010-02-08 |
2019-06-28 |
Regeneron Pharmaceuticals, Inc. |
Miš z navadno lahko verigo
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
RU2577125C2
(ru)
|
2010-02-10 |
2016-03-10 |
Фуджифилм Ри Фарма Ко., Лтд. |
Меченное радиоактивным металлом антитело против кадгерина
|
EP2533810B1
(de)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20-antikörper und ihre verwendung
|
US20120321557A1
(en)
|
2010-02-26 |
2012-12-20 |
Forerunner Pharma Research Co., Ltd. |
Anti-icam3 antibody and use thereof
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
CN103003307B
(zh)
|
2010-03-10 |
2017-08-11 |
根马布股份公司 |
抗c‑MEt的单克隆抗体
|
JP2013522313A
(ja)
|
2010-03-17 |
2013-06-13 |
アボツト・リサーチ・ベー・フエー |
抗神経成長因子(ngf)抗体組成物
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
LT3248462T
(lt)
|
2010-03-31 |
2024-05-27 |
Ablexis, Llc |
Pelių genų inžinerija, skirta chimerinių antikūnų gamybai
|
EA024701B1
(ru)
|
2010-04-13 |
2016-10-31 |
Селлдекс Терапьютикс Инк. |
Антитела, связывающие cd27 человека, и их применение
|
MX353144B
(es)
|
2010-04-20 |
2017-12-20 |
Genmab As |
Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
|
US9011852B2
(en)
|
2010-04-30 |
2015-04-21 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
SG185366A1
(en)
|
2010-05-04 |
2012-12-28 |
Merrimack Pharmaceuticals Inc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
ES2949159T3
(es)
|
2010-05-06 |
2023-09-26 |
Novartis Ag |
Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6)
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
CN103153339B
(zh)
|
2010-05-27 |
2021-05-04 |
根马布股份公司 |
针对her2表位的单克隆抗体
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
DK2578231T3
(da)
|
2010-05-28 |
2022-12-12 |
Chugai Pharmaceutical Co Ltd |
Antitumor-t-celle-reaktionsforstærker
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
EP2580243B1
(de)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antikörper gegen menschliches cd38
|
BR112012031727B1
(pt)
|
2010-06-15 |
2022-03-29 |
Genmab A/S |
Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
|
AU2011270959A1
(en)
|
2010-06-22 |
2013-01-10 |
Musc Foundation For Research Development |
Antibodies to the C3d fragment of complement component 3
|
EP3327035A1
(de)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
|
US9485812B2
(en)
|
2010-07-08 |
2016-11-01 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
KR20130097156A
(ko)
|
2010-07-26 |
2013-09-02 |
트리아니, 인코포레이티드 |
트랜스제닉 동물 및 이의 사용 방법
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
DK2601298T3
(en)
|
2010-08-02 |
2017-02-27 |
Regeneron Pharma |
Mice generating binding proteins comprising VL domains
|
WO2012018404A2
(en)
|
2010-08-06 |
2012-02-09 |
U3 Pharma Gmbh |
Use of her3 binding agents in prostate treatment
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
AR083035A1
(es)
|
2010-09-17 |
2013-01-30 |
Baxter Int |
ESTABILIZACION DE INMUNOGLOBULINAS MEDIANTE UNA FORMULACION ACUOSA CON HISTIDINA A pH ACIDO DEBIL A NEUTRO, COMPOSICION ACUOSA DE INMUNOGLOBULINA
|
US9068014B2
(en)
|
2010-09-23 |
2015-06-30 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
WO2012043747A1
(ja)
|
2010-09-30 |
2012-04-05 |
独立行政法人理化学研究所 |
グリオーマの治療方法、グリオーマの検査方法、所望の物質をグリオーマに送達させる方法、及びそれらの方法に用いられる薬剤
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
BR112013010136A2
(pt)
|
2010-10-25 |
2019-09-24 |
Univ Minnesota |
vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
|
PT2634194T
(pt)
|
2010-10-29 |
2018-10-19 |
Perseus Proteomics Inc |
Anticorpos anti-cdh3 possuidores de elevada capacidade de internalização
|
EP2644698B1
(de)
|
2010-11-17 |
2018-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
Multispezifisches antigenbindendes molekül mit einer blutgerinnungsfaktor-viii-wechselfunktion
|
EP2643353A1
(de)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispezifische moleküle
|
RU2663123C2
(ru)
|
2010-11-30 |
2018-08-01 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующий цитотоксичность терапевтический агент
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
US9085772B2
(en)
|
2010-12-27 |
2015-07-21 |
National University Corporation Nagoya University |
Method for suppressing receptor tyrosine kinase-mediated pro-survival signaling in cancer cell
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
WO2012133782A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
BR112013021526B1
(pt)
|
2011-02-25 |
2021-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Polipeptídio variante, métodos para manter ou diminuir as atividades de ligação a fcgriia (tipo r) e fcgriia (tipo h) e aumentar a atividade de ligação a fcgriib de um polipeptídio e para a supressão da produção de um anticorpo contra um polipeptídio compreendendo a região fc do anticorpo, métodos para a produção do referido polipeptídio com atividades de ligação mantidas ou diminuídas e aumentada e para a produção suprimida de um anticorpo, composição farmacêutica e uso de um polipeptídio
|
WO2012118693A1
(en)
|
2011-02-28 |
2012-09-07 |
Northshore University Healthsystem |
Methods of diagnosing clostridium difficile infection
|
JP5948683B2
(ja)
|
2011-02-28 |
2016-07-06 |
国立研究開発法人国立循環器病研究センター |
悪性腫瘍転移抑制用医薬
|
AU2012240231B2
(en)
|
2011-04-04 |
2017-05-25 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
AU2012239997A1
(en)
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
WO2012136552A1
(en)
|
2011-04-08 |
2012-10-11 |
H. Lundbeck A/S |
ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
WO2012144208A1
(ja)
|
2011-04-18 |
2012-10-26 |
国立大学法人東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
CN103796678B
(zh)
|
2011-04-20 |
2018-02-27 |
健玛保 |
针对her2的双特异性抗体
|
JP2014514314A
(ja)
|
2011-04-20 |
2014-06-19 |
ゲンマブ エー/エス |
Her2およびcd3に対する二重特異性抗体
|
EP2702077A2
(de)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
US9890218B2
(en)
|
2011-06-30 |
2018-02-13 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
US10323081B2
(en)
|
2011-07-06 |
2019-06-18 |
Genmag A/S |
Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
US9238689B2
(en)
|
2011-07-15 |
2016-01-19 |
Morpho Sys AG |
Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
|
US9156911B2
(en)
|
2011-07-18 |
2015-10-13 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
WO2013012022A1
(ja)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
WO2013017691A1
(en)
|
2011-08-04 |
2013-02-07 |
Medizinische Universität Innsbruck |
Cahgt1p inhibitors for use in the treatment of candidiasis
|
RS61946B1
(sr)
|
2011-08-05 |
2021-07-30 |
Regeneron Pharma |
Humanizovani miševi univerzalnog lakog lakca
|
JP5925783B2
(ja)
|
2011-08-12 |
2016-05-25 |
国立感染症研究所長 |
アスペルギルスフミガーツス感染症の検査、予防及び治療のための方法並びに組成物
|
EP2749572A4
(de)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
Neuer anti-ddr1-antikörper mit antitumoraktivität
|
WO2013035824A1
(ja)
|
2011-09-07 |
2013-03-14 |
ファーマロジカルズ・リサーチ プライベート リミテッド |
癌幹細胞の分離
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
WO2013047752A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
US10024867B2
(en)
|
2011-09-30 |
2018-07-17 |
Chugai Seiyaku Kabushiki Kaisha |
Ion concentration-dependent binding molecule library
|
MX366968B
(es)
|
2011-09-30 |
2019-08-01 |
Chugai Pharmaceutical Co Ltd |
Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
|
JP6271251B2
(ja)
|
2011-10-05 |
2018-01-31 |
中外製薬株式会社 |
糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子
|
EP2766033B1
(de)
|
2011-10-14 |
2019-11-20 |
Novartis AG |
Antikörper und verfahren für wnt-signalwegbedingte erkrankungen
|
EP3216871B1
(de)
|
2011-10-17 |
2021-12-22 |
Regeneron Pharmaceuticals, Inc. |
Mäuse mit eingeschränkten schweren immunglobulinketten
|
AU2012328322A1
(en)
|
2011-10-27 |
2014-06-12 |
Genmab A/S |
Production of heterodimeric proteins
|
US20140302511A1
(en)
|
2011-10-28 |
2014-10-09 |
Pharmalogicals Research Pte. Ltd. |
Cancer stem cell-specific molecule
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
ES2697674T3
(es)
|
2011-11-01 |
2019-01-25 |
Bionomics Inc |
Procedimientos para bloquear el crecimiento de células madre cancerosas
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104168922A
(zh)
|
2011-11-16 |
2014-11-26 |
安姆根有限公司 |
治疗表皮生长因子缺失突变体viii相关疾病的方法
|
BR112014013081A2
(pt)
|
2011-11-30 |
2020-10-20 |
Chugai Seiyaku Kabushiki Kaisha |
veículo contendo fármaco em célula para formação de um complexo imune
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
KR102083957B1
(ko)
|
2011-12-05 |
2020-03-04 |
노파르티스 아게 |
표피 성장 인자 수용체 3 (her3)에 대한 항체
|
KR20140103135A
(ko)
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
AU2012356170B2
(en)
|
2011-12-21 |
2016-06-16 |
Novartis Ag |
Compositions and methods for antibodies targeting Factor P
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CN104185681A
(zh)
|
2012-02-01 |
2014-12-03 |
卡姆普根有限公司 |
C1orf32抗体及其用于治疗癌症的用途
|
PT2812443T
(pt)
|
2012-02-06 |
2019-09-05 |
Inhibrx Inc |
Anticorpos cd47 e métodos de utilização dos mesmos
|
SG11201404751UA
(en)
|
2012-02-09 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
US20160046693A1
(en)
|
2012-02-24 |
2016-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-Binding Molecule for Promoting Disappearance of Antigen via Fc gamma RIIB
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
WO2013150623A1
(ja)
|
2012-04-04 |
2013-10-10 |
株式会社ペルセウスプロテオミクス |
抗cdh3(p-カドヘリン)抗体の薬剤コンジュゲート
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
US9416189B2
(en)
|
2012-05-11 |
2016-08-16 |
Microbial Chemistry Research Foundation |
Anti-CXADR antibody
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
RU2743463C2
(ru)
|
2012-05-30 |
2021-02-18 |
Чугаи Сейяку Кабусики Кайся |
Специфичная к ткани-мишени антигенсвязывающая молекула
|
SG10201609535TA
(en)
*
|
2012-06-05 |
2017-01-27 |
Regeneron Pharma |
Methods for making fully human bispecific antibodies using a common light chain
|
MX2014015195A
(es)
|
2012-06-11 |
2015-02-17 |
Amgen Inc |
Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos.
|
EP3597037B1
(de)
|
2012-06-12 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Humanisierte nichtmenschliche tiere mit eingeschränkten schwerkettigen immunglobulin-loci
|
JP6628966B2
(ja)
|
2012-06-14 |
2020-01-15 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
EP2864352B1
(de)
|
2012-06-22 |
2018-08-08 |
The Trustees Of Dartmouth College |
Neuartige vista-ig-konstrukte und verwendung von vista-ig zur behandlung von autoimmun-, allergischen und entzündungserkrankungen
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN104736174B
(zh)
|
2012-07-06 |
2019-06-14 |
根马布私人有限公司 |
具有三重突变的二聚体蛋白质
|
EP3632462A1
(de)
|
2012-07-06 |
2020-04-08 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
WO2014007402A1
(ja)
|
2012-07-06 |
2014-01-09 |
京都府公立大学法人 |
眼細胞の分化マーカーおよび分化制御
|
WO2014021339A1
(ja)
|
2012-07-30 |
2014-02-06 |
国立大学法人名古屋大学 |
ヒトミッドカインに対するモノクローナル抗体
|
CA2882272C
(en)
|
2012-08-24 |
2023-08-29 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc region variant
|
EP3597747B1
(de)
|
2012-08-24 |
2023-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Maus-fgcgammarii-spezifischer fc-antikörper
|
AU2013309506A1
(en)
|
2012-09-02 |
2015-03-12 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
WO2014042251A1
(ja)
|
2012-09-13 |
2014-03-20 |
中外製薬株式会社 |
遺伝子ノックイン非ヒト動物
|
EA031631B1
(ru)
|
2012-09-27 |
2019-01-31 |
Чугаи Сеияку Кабушики Каиша |
Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
|
CA2886326C
(en)
|
2012-09-28 |
2021-11-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for evaluating blood coagulation reaction
|
EP3489258A1
(de)
|
2012-11-08 |
2019-05-29 |
Eleven Biotherapeutics, Inc. |
Il6-antagonisten und verwendungen davon
|
ES2689782T3
(es)
|
2012-11-08 |
2018-11-15 |
University Of Miyazaki |
Anticuerpo capaz de reconocer específicamente un receptor de transferrina
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
PT2928921T
(pt)
|
2012-12-05 |
2021-04-06 |
Novartis Ag |
Composições e métodos para anticorpos que visam epo
|
EP2935589A1
(de)
|
2012-12-18 |
2015-10-28 |
Novartis AG |
Zusammensetzungen und verfahren unter verwendung eines an hyaluronan bindenden peptid-tags
|
ES2876009T3
(es)
|
2012-12-27 |
2021-11-11 |
Chugai Pharmaceutical Co Ltd |
Polipéptido heterodimerizado
|
US9938344B2
(en)
|
2012-12-28 |
2018-04-10 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
KR20160007478A
(ko)
|
2013-01-10 |
2016-01-20 |
젠맵 비. 브이 |
인간 IgG1 Fc 영역 변이체 및 그의 용도
|
EP2948478B1
(de)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antikörper gegen cdh19 für melanome
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
EP4137518A1
(de)
|
2013-02-06 |
2023-02-22 |
Inhibrx, Inc. |
Nicht-plättchen-depletierende und nicht-erythrozyten-depletierende cd47-antikörpern und verfahren zur verwendung davon
|
UY35315A
(es)
|
2013-02-08 |
2014-09-30 |
Novartis Ag |
Anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorios
|
JP6357113B2
(ja)
|
2013-02-08 |
2018-07-11 |
株式会社医学生物学研究所 |
ヒトnrg1タンパク質に対する抗体
|
DK2840892T3
(en)
|
2013-02-20 |
2018-07-23 |
Regeneron Pharma |
Non-human animals with modified heavy chain immunoglobulin sequences
|
US9429584B2
(en)
|
2013-02-28 |
2016-08-30 |
National Cancer Center |
Antibody against insoluble fibrin
|
WO2014136910A1
(ja)
|
2013-03-08 |
2014-09-12 |
国立大学法人大阪大学 |
ペリオスチンのExon-21部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014159239A2
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Antibodies against notch 3
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
LT2970449T
(lt)
|
2013-03-15 |
2019-11-25 |
Amgen Res Munich Gmbh |
Viengrandės surišančios molekulės, apimančios n galo abp
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
WO2014174596A1
(ja)
|
2013-04-23 |
2014-10-30 |
株式会社医学生物学研究所 |
ヘパリン結合上皮増殖因子様増殖因子に対する機能性モノクローナル抗体
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
CA2912526C
(en)
|
2013-05-16 |
2021-09-14 |
Kyoto University |
Method for determining prognosis of cancer
|
WO2014186877A1
(en)
|
2013-05-24 |
2014-11-27 |
Uger Marni Diane |
FasR ANTIBODIES FOR DIAGNOSTIC AND THERAPEUTIC USE
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
BR112015032414A2
(pt)
|
2013-06-24 |
2017-11-07 |
Chugai Pharmaceutical Co Ltd |
agente terapêutico compreendendo anticorpo antiepirregulina humanizado como ingrediente ativo para carcinoma de pulmão de célula não pequena excluindo adenocarcinoma
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
BR112016002198A2
(pt)
|
2013-08-14 |
2017-09-12 |
Novartis Ag |
métodos de tratamento de miosite por corpos de inclusão esporádica
|
EP3033356B1
(de)
|
2013-08-14 |
2020-01-15 |
Sachdev Sidhu |
Antikörper gegen frizzled proteine und verwendung davon
|
US20160193308A1
(en)
|
2013-09-04 |
2016-07-07 |
Osaka University |
Dpp-4-targeting vaccine for treating diabetes
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
TW201546284A
(zh)
|
2013-10-01 |
2015-12-16 |
Kymab Ltd |
動物模式及治療分子
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
EP3070167A4
(de)
|
2013-11-06 |
2017-06-07 |
Osaka University |
Antikörper mit breiter neutralisierender aktivität bei einem gruppe-1-influenza-a-virus
|
CA2929044A1
(en)
|
2013-11-11 |
2015-05-14 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified antibody variable region
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
EP3763813A1
(de)
|
2013-12-04 |
2021-01-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigenbindende moleküle, deren antigenbindende aktivität je nach konzentration von verbindungen variiert, und bibliotheken besagter moleküle
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
KR101836756B1
(ko)
|
2013-12-27 |
2018-03-08 |
오사카 유니버시티 |
Il-17a를 표적화하는 백신
|
MX2016008498A
(es)
|
2013-12-27 |
2016-10-07 |
Chugai Pharmaceutical Co Ltd |
Metodo para purificar anticuerpo que tiene bajo punto isoelectrico.
|
TW201609093A
(zh)
|
2013-12-27 |
2016-03-16 |
Chugai Pharmaceutical Co Ltd |
Fgfr門控蛋白變異基因及以其爲標的之醫藥
|
US10106623B2
(en)
|
2014-02-12 |
2018-10-23 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
US10881085B2
(en)
|
2014-03-21 |
2021-01-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
SG10201808083VA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
SG11201607772WA
(en)
|
2014-03-31 |
2016-10-28 |
Debiopharm Int Sa |
Fgfr fusions
|
KR102352573B1
(ko)
|
2014-04-04 |
2022-01-18 |
바이오노믹스 인코포레이티드 |
Lgr5에 결합하는 인간화된 항체들
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
SG10201810507WA
(en)
|
2014-06-06 |
2018-12-28 |
Bristol Myers Squibb Co |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
TWI831106B
(zh)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
EP3161001A2
(de)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Il17-a spezifische antikörper die mit hyaluronan bindenden peptid-marker fusioniert sind
|
WO2015198243A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2015198240A2
(en)
|
2014-06-25 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long acting proteins
|
WO2016007414A1
(en)
|
2014-07-08 |
2016-01-14 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
AU2015286569B2
(en)
|
2014-07-11 |
2021-04-15 |
Genmab A/S |
Antibodies binding AXL
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
WO2016016415A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
CA2956471A1
(en)
|
2014-07-31 |
2016-02-04 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
ES2726645T3
(es)
|
2014-08-01 |
2019-10-08 |
Inst Nat Sante Rech Med |
Un anticuerpo anti-CD45RC para usar como medicamento
|
WO2016020880A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
WO2016020882A2
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoetin-like 4 (angptl4) antibodies and methods of use
|
JP6858559B2
(ja)
|
2014-08-20 |
2021-04-14 |
中外製薬株式会社 |
蛋白質溶液の粘度測定方法
|
SG10201902924RA
(en)
|
2014-10-03 |
2019-05-30 |
Massachusetts Inst Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
US10738078B2
(en)
|
2014-11-03 |
2020-08-11 |
Bristol-Myers Squibb Company |
Use of caprylic acid precipitation for protein purification
|
BR112017009297B1
(pt)
|
2014-11-05 |
2024-02-15 |
Annexon, Inc |
Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses
|
SG11201703574VA
(en)
|
2014-11-07 |
2017-05-30 |
Eleven Biotherapeutics Inc |
Improved il-6 antibodies
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
NZ731633A
(en)
|
2014-11-21 |
2022-01-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
EP3945096A1
(de)
|
2014-12-19 |
2022-02-02 |
Regenesance B.V. |
Antikörper zur bindung von humanem c6 und verwendungen davon
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
TWI805046B
(zh)
|
2015-02-27 |
2023-06-11 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
JP6807859B2
(ja)
|
2015-03-13 |
2021-01-06 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
クロマトグラフィーにおける不純物を取り除くためのアルカリ洗浄の使用
|
EP3271403A1
(de)
*
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Nichtmenschliche tiere zur selektion von leichtkettigen variablen regionen zur antigenbindung
|
US20180105554A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran sulfate to enhance protein a affinity chromatography
|
US20180105555A1
(en)
|
2015-03-20 |
2018-04-19 |
Bristol-Myers Squibb Company |
Use of dextran for protein purification
|
EP4276116A3
(de)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispezifische antikörperkonstrukte für cdh3 und cd3
|
CA2978038A1
(en)
|
2015-04-17 |
2016-10-20 |
F. Hoffmann-La Roche Ag |
Combination therapy with coagulation factors and multispecific antibodies
|
CR20200517A
(es)
|
2015-04-28 |
2021-01-12 |
Mitsubishi Tanabe Pharma Corp |
PROTEINA DE UNION A RGma Y SUS USO
|
PE20180926A1
(es)
|
2015-05-29 |
2018-06-08 |
Bristol Myers Squibb Co |
Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos
|
BR112017021484A2
(pt)
|
2015-06-05 |
2018-07-03 |
Novartis Ag |
anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
JP2018526977A
(ja)
|
2015-06-29 |
2018-09-20 |
ザ ロックフェラー ユニヴァーシティ |
アゴニスト活性が増強されたcd40に対する抗体
|
EP3319993B1
(de)
|
2015-07-10 |
2020-01-15 |
Genmab A/S |
Axl-spezifische antikörper-wirkstoff-konjugate zur krebsbehandlung
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
JP6913078B2
(ja)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウの短縮型Asp421エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
|
US10358503B2
(en)
|
2015-08-13 |
2019-07-23 |
New York University |
Antibody-based molecules selective for the {P}Ser404 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
|
AU2016320748B2
(en)
|
2015-09-09 |
2019-05-02 |
Novartis Ag |
Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
|
EP3347377B1
(de)
|
2015-09-09 |
2021-02-17 |
Novartis AG |
Thymus-stroma-lymphopoietin(tslp)-bindende antikörper und verfahren zur verwendung der antikörper
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
EP3378488A4
(de)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Verfahren zur verbesserung der humoralen immunreaktion
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
PT3383920T
(pt)
|
2015-11-30 |
2024-04-15 |
Univ California |
Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
|
EP3383903A1
(de)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Humane ip-10-antikörper und deren verwendung
|
EP3384030A4
(de)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
Verbesserte immunglobulindiversität
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
JP6954842B2
(ja)
|
2015-12-25 |
2021-10-27 |
中外製薬株式会社 |
増強された活性を有する抗体及びその改変方法
|
EP3851457A1
(de)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Gegen cll-1 gerichtete multispezifische moleküle
|
PL3411404T3
(pl)
|
2016-02-03 |
2023-02-13 |
Amgen Research (Munich) Gmbh |
Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US10301391B2
(en)
|
2016-02-03 |
2019-05-28 |
Amgen Research (Munich) Gmbh |
BCMA and CD3 bispecific T cell engaging antibody constructs
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
MX2018010672A
(es)
|
2016-03-04 |
2019-05-27 |
Univ Rockefeller |
Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
|
EA201891983A8
(ru)
|
2016-03-04 |
2020-05-28 |
Бристол-Майерс Сквибб Компани |
Комбинированная терапия антителами к cd73
|
CA3016424A1
(en)
|
2016-03-14 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
KR102413037B1
(ko)
|
2016-03-15 |
2022-06-23 |
메르사나 테라퓨틱스, 인코포레이티드 |
Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
|
JP2019509322A
(ja)
|
2016-03-22 |
2019-04-04 |
バイオノミクス リミテッド |
抗lgr5モノクローナル抗体の投与
|
US10765724B2
(en)
|
2016-03-29 |
2020-09-08 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
EA201892362A1
(ru)
|
2016-04-18 |
2019-04-30 |
Селлдекс Терапьютикс, Инк. |
Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
SG11201809793UA
(en)
|
2016-05-09 |
2018-12-28 |
Bristol Myers Squibb Co |
Tl1a antibodies and uses thereof
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(bmp6)의 억제제를 사용한 질병의 치료 방법
|
GEP20217222B
(en)
|
2016-07-12 |
2021-02-10 |
Lundbeck A/S H |
Antibodies specific for hyperphosphorylated tau and methods of use thereof
|
SG11201900026TA
(en)
|
2016-07-14 |
2019-01-30 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
WO2018029586A1
(en)
|
2016-08-07 |
2018-02-15 |
Novartis Ag |
Mrna-mediated immunization methods
|
US10947268B2
(en)
|
2016-08-12 |
2021-03-16 |
Bristol-Myers Squibb Company |
Methods of purifying proteins
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
MX2019002510A
(es)
|
2016-09-06 |
2019-06-24 |
Chugai Pharmaceutical Co Ltd |
Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
|
TW201825674A
(zh)
|
2016-09-09 |
2018-07-16 |
美商艾斯合顧問有限公司 |
表現雙特異性接合分子的溶瘤病毒
|
AU2017336799B2
(en)
|
2016-09-30 |
2023-08-31 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-IL23 specific antibody
|
CU20210030A7
(es)
|
2016-10-13 |
2021-11-04 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteína de envoltura del virus zika
|
US11339209B2
(en)
|
2016-11-14 |
2022-05-24 |
Novartis Ag |
Compositions, methods, and therapeutic uses related to fusogenic protein minion
|
RU2019114679A
(ru)
|
2016-11-15 |
2020-12-17 |
Х. Лундбекк А/С |
Средства, пути применения и способы лечения синуклеопатии
|
MX2019005661A
(es)
|
2016-11-16 |
2019-10-07 |
Janssen Biotech Inc |
Método para tratar la psoriasis con el anticuerpo específico anti-il23.
|
TWI776827B
(zh)
|
2016-11-28 |
2022-09-11 |
日商中外製藥股份有限公司 |
能夠調節配體結合活性的配體結合分子
|
MA47019A
(fr)
|
2016-12-16 |
2021-04-21 |
H Lundbeck As |
Agents, utilisations et procédés
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
JP7062669B2
(ja)
|
2016-12-23 |
2022-05-06 |
ブリストル-マイヤーズ スクイブ カンパニー |
改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンg4の設計
|
MA47205A
(fr)
|
2017-01-04 |
2019-11-13 |
H Lundbeck As |
Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
|
WO2018129451A2
(en)
|
2017-01-09 |
2018-07-12 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
EP3573658A4
(de)
|
2017-01-30 |
2021-07-21 |
Janssen Biotech, Inc. |
Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
JP2020506947A
(ja)
|
2017-02-07 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
AU2018218557B9
(en)
|
2017-02-08 |
2021-06-24 |
Novartis Ag |
FGF21 mimetic antibodies and uses thereof
|
JP7136790B2
(ja)
|
2017-02-17 |
2022-09-13 |
ブリストル-マイヤーズ スクイブ カンパニー |
アルファ-シヌクレインに対する抗体およびその使用
|
KR102628323B1
(ko)
|
2017-03-24 |
2024-01-22 |
노바르티스 아게 |
심장질환 예방 및 치료 방법
|
JP7050333B2
(ja)
|
2017-03-24 |
2022-04-08 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
KR102660861B1
(ko)
|
2017-03-30 |
2024-04-25 |
더 존스 홉킨스 유니버시티 |
생체거대분자의 정제를 위한 초분자 고친화성 단백질-결합 시스템
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
US20200109390A1
(en)
|
2017-04-27 |
2020-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Coagulation factor ix with improved pharmacokinetics
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
JP7379323B2
(ja)
|
2017-08-18 |
2023-11-14 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
タンパク質精製のための超分子フィラメント集合体
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
AU2018376309A1
(en)
|
2017-11-28 |
2020-06-25 |
Chugai Seiyaku Kabushiki Kaisha |
Ligand-binding molecule having adjustable ligand-binding activity
|
EA202091422A1
(ru)
|
2017-12-11 |
2020-08-28 |
Эмджен Инк. |
Способ непрерывного производства продуктов на основе биспецифических антител
|
EP3498293A1
(de)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Behandlung monogener erkrankungen mit einem anti-cd45rc-antikörper
|
JP7314146B2
(ja)
|
2017-12-28 |
2023-07-25 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
SG11202005323SA
(en)
|
2018-01-12 |
2020-07-29 |
Bristol Myers Squibb Co |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
CN111886255A
(zh)
|
2018-01-12 |
2020-11-03 |
百时美施贵宝公司 |
抗tim3抗体及其用途
|
WO2019151418A1
(ja)
|
2018-01-31 |
2019-08-08 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
WO2019171252A1
(en)
|
2018-03-05 |
2019-09-12 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202003565A
(zh)
|
2018-03-23 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
抗mica及/或micb抗體及其用途
|
EP3774882A1
(de)
|
2018-03-29 |
2021-02-17 |
Bristol-Myers Squibb Company |
Verfahren zur reinigung monomerer monoklonaler antikörper
|
BR112020022265A2
(pt)
|
2018-05-07 |
2021-02-23 |
Genmab A/S |
método para tratar câncer em um indivíduo, e, estojo.
|
KR20210044183A
(ko)
|
2018-05-07 |
2021-04-22 |
젠맵 에이/에스 |
항-pd-1 항체 및 항-조직 인자 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
US20210196568A1
(en)
|
2018-05-21 |
2021-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
Lyophilized formulation sealed in glass container
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
CN112533635A
(zh)
|
2018-07-10 |
2021-03-19 |
田边三菱制药株式会社 |
末梢神经病变或者伴随确认到末梢神经病变或星形胶质细胞病变的疾病的疼痛的预防或治疗方法
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
PE20211400A1
(es)
|
2018-08-03 |
2021-07-27 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cldn18.2 y cd3
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
JP2022502076A
(ja)
|
2018-09-18 |
2022-01-11 |
メリマック ファーマシューティカルズ インコーポレーティッド |
抗tnfr2抗体およびその使用
|
CA3113837C
(en)
|
2018-09-24 |
2022-07-12 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
UA127902C2
(uk)
|
2018-10-30 |
2024-02-07 |
Генмаб А/С |
Застосування комбінації антитіла проти vegf і кон'югата антитіло проти тканинного фактора-лікарський засіб для лікування раку
|
US11274150B2
(en)
|
2018-11-16 |
2022-03-15 |
Bristol-Myers Squibb Company |
Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
|
EP3883607A4
(de)
|
2018-11-20 |
2022-08-17 |
Janssen Biotech, Inc. |
Sicheres und effizientes verfahren zur behandlung von psoriasis mit anti-il-23-spezifischem antikörper
|
MA54562A
(fr)
|
2018-12-18 |
2021-10-27 |
Janssen Biotech Inc |
Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
|
WO2020148651A1
(en)
|
2019-01-15 |
2020-07-23 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
|
SG11202107951YA
(en)
|
2019-01-22 |
2021-08-30 |
Bristol Myers Squibb Co |
Antibodies against il-7r alpha subunit and uses thereof
|
US20220064278A1
(en)
|
2019-01-23 |
2022-03-03 |
Janssen Biotech, Inc. |
Anti-TNF Antibody Compositions for Use in Methods for the Treatment of Psoriatic Arthritis
|
EP3915581A4
(de)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
Neuartige krebsantigene und antikörper dieser antigene
|
US20220290128A1
(en)
|
2019-02-04 |
2022-09-15 |
National University Corporation Ehime University |
CAR LIBRARY AND scFv MANUFACTURING METHOD
|
EP3932952A4
(de)
|
2019-02-28 |
2022-11-30 |
Juntendo Educational Foundation |
An trunkiertes mutantes calreticulin bindende antikörper und diagnostisches, prophylaktisches oder therapeutisches arzneimittel für myeloproliferative neoplasmen
|
US20220281990A1
(en)
|
2019-03-01 |
2022-09-08 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
MA55282A
(fr)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech Inc |
Procédés de fabrication pour la production de compositions d'anticorps anti-tnf
|
EP3938391A1
(de)
|
2019-03-14 |
2022-01-19 |
Janssen Biotech, Inc. |
Verfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
|
EA202192508A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
KR20210141990A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
|
MA55383A
(fr)
|
2019-03-18 |
2022-01-26 |
Janssen Biotech Inc |
Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
|
EP3943108A4
(de)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-bindendes molekül mit antigen-bindender domäne mit veränderlicher bindungsaktivität gegenüber antigen in abhängigkeit von mta und bibliothek zur gewinnung der antigen-bindenden domäne
|
KR20210144819A
(ko)
|
2019-03-29 |
2021-11-30 |
브리스톨-마이어스 스큅 컴퍼니 |
크로마토그래피 수지의 소수성을 측정하는 방법
|
SG11202110986YA
(en)
|
2019-04-10 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Method for purifying fc region-modified antibody
|
JP7501876B2
(ja)
|
2019-04-17 |
2024-06-18 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
EP3976648A1
(de)
|
2019-06-03 |
2022-04-06 |
Janssen Biotech, Inc. |
Anti-tnf-antikörperzusammensetzungen und verfahren zur behandlung von aktiver psoriasis-arthritis
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
AU2020288499A1
(en)
|
2019-06-05 |
2022-01-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
KR20220019785A
(ko)
|
2019-06-12 |
2022-02-17 |
노파르티스 아게 |
나트륨이뇨 펩티드 수용체 1 항체 및 사용 방법
|
CA3137494A1
(en)
|
2019-06-13 |
2020-12-17 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
JP2022542890A
(ja)
|
2019-07-26 |
2022-10-07 |
アムジエン・インコーポレーテツド |
抗il13抗原結合タンパク質
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
JP2022547135A
(ja)
|
2019-09-10 |
2022-11-10 |
アムジエン・インコーポレーテツド |
増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
WO2021091815A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
MX2022005222A
(es)
|
2019-11-07 |
2022-06-08 |
Genmab As |
Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
JP2023509373A
(ja)
|
2019-12-20 |
2023-03-08 |
ノヴァロック バイオセラピューティクス, リミテッド |
抗インターロイキン-23 p19抗体およびそれの使用方法
|
UY38995A
(es)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
AU2020414409A1
(en)
|
2019-12-27 |
2022-06-16 |
Affimed Gmbh |
Method for the production of bispecific FcyRIIl x CD30 antibody construct
|
US20230090965A1
(en)
|
2020-01-15 |
2023-03-23 |
Osaka University |
Prophylactic or therapeutic agent for dementia
|
EP4091632A1
(de)
|
2020-01-15 |
2022-11-23 |
Osaka University |
Mittel zur vorbeugung oder behandlung von diabetischer autonomer neuropathie
|
WO2021150824A1
(en)
|
2020-01-22 |
2021-07-29 |
Amgen Research (Munich) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
KR20220155338A
(ko)
|
2020-03-19 |
2022-11-22 |
암젠 인크 |
뮤신 17에 대한 항체 및 이의 용도
|
EP4129333A4
(de)
|
2020-03-27 |
2024-06-12 |
PhotoQ3 Inc. |
Pharmazeutisches arzneimittel zur zerstörung von tumorzellen
|
CN115379858A
(zh)
|
2020-04-06 |
2022-11-22 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
JP2023523760A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
免疫グロブリン変異体
|
JP2023523794A
(ja)
|
2020-05-01 |
2023-06-07 |
ノバルティス アーゲー |
人工操作免疫グロブリン
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
WO2021235537A1
(ja)
|
2020-05-22 |
2021-11-25 |
中外製薬株式会社 |
凝固第viii因子(f.viii)機能代替活性を有する物質を中和する抗体
|
EP4157874A2
(de)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Die nebenwirkungen mindernde verabreichung eines bispezifischen antikörperkonstrukts, das an cd33 und cd3 bindet
|
EP4174071A1
(de)
|
2020-06-24 |
2023-05-03 |
The University of Tokyo |
Photosensibilisierender farbstoff
|
TW202216210A
(zh)
|
2020-06-29 |
2022-05-01 |
丹麥商珍美寶股份有限公司 |
抗組織因子抗體-藥物共軛體類和彼等於治療癌症之用途
|
WO2022014703A1
(ja)
|
2020-07-17 |
2022-01-20 |
田辺三菱製薬株式会社 |
筋疾患の予防または治療剤
|
WO2022025030A1
(ja)
|
2020-07-28 |
2022-02-03 |
中外製薬株式会社 |
新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
JP2023534765A
(ja)
|
2020-08-07 |
2023-08-10 |
フォーティス セラピューティクス,インク. |
免疫複合体を標的とするcd46およびその使用方法
|
IL300764A
(en)
|
2020-08-27 |
2023-04-01 |
Juntendo Educational Found |
Antibody and composition of calr-cd3 mutant anti-clotting drugs
|
JP2023540526A
(ja)
|
2020-09-04 |
2023-09-25 |
ノヴァロック バイオセラピューティクス, リミテッド |
ネクチン-4抗体およびそれの使用
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
WO2022096716A2
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
KR20230098335A
(ko)
|
2020-11-06 |
2023-07-03 |
암젠 인크 |
클리핑 비율이 감소된 항원 결합 도메인
|
US20230406929A1
(en)
|
2020-11-06 |
2023-12-21 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
AU2021374036A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs selectively binding to cldn6 and cd3
|
WO2022108931A2
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
EP4259661A1
(de)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reverse bindemittel für anti-natriuretische peptidrezeptor-1 (npr1)-antikörper und verwendungen davon
|
AR124914A1
(es)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
JP2024510588A
(ja)
|
2021-03-12 |
2024-03-08 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体による、tnf療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
|
WO2022191306A1
(ja)
|
2021-03-12 |
2022-09-15 |
中外製薬株式会社 |
重症筋無力症の治療または予防用の医薬組成物
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
AU2022246675A1
(en)
|
2021-04-02 |
2023-10-19 |
Amgen Inc. |
Mageb2 binding constructs
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
CD20 and CD22 targeting antigen-binding molecules for use in proliferative diseases
|
EP4367137A1
(de)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Herstellungsverfahren zur herstellung von anti-tnf-antikörperzusammensetzungen
|
IL309987A
(en)
|
2021-07-09 |
2024-03-01 |
Janssen Biotech Inc |
Production methods for the production of anti-IL12/IL23 antibody compositions
|
KR20240034218A
(ko)
|
2021-07-09 |
2024-03-13 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생산하기 위한 제조 방법
|
AU2022320948A1
(en)
|
2021-07-30 |
2024-01-18 |
Affimed Gmbh |
Duplexbodies
|
CN117999098A
(zh)
|
2021-09-24 |
2024-05-07 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
KR20240082388A
(ko)
|
2021-10-08 |
2024-06-10 |
추가이 세이야쿠 가부시키가이샤 |
프리필드 시린지 제제의 조제 방법
|
IL312401A
(en)
|
2021-10-29 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
IL312110A
(en)
|
2021-10-29 |
2024-06-01 |
Seagen Inc |
Cancer treatment methods with a combination of anti-PD-1 antibody and antibody-CD30 conjugate
|
CA3233696A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
CA3239216A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
TW202408583A
(zh)
|
2022-05-06 |
2024-03-01 |
丹麥商珍美寶股份有限公司 |
使用抗組織因子抗體-藥物共軛體以治療癌症之方法
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
US20240199734A1
(en)
|
2022-11-22 |
2024-06-20 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2024127366A1
(en)
|
2022-12-16 |
2024-06-20 |
Pheon Therapeutics Ltd |
Antibodies to cub domain-containing protein 1 (cdcp1) and uses thereof
|